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Abstract
Purpose To assess the heterogeneity of magnetic resonance
(MR) imaging characteristics in primary lymphoma of bone
(PLB), in particular the non-aggressive appearance.
Subjects and methods In a retrospective study, MR imaging
features were analyzed in 29 patients with histologically
proven PLB. The following parameters were evaluated:
tumor size, bone marrow and extension into soft tissues,
signal characteristics of bone marrow and soft-tissue com-
ponents, including enhancement, and involvement of
cortical bone (complete disruption, focal destruction,
permeative destruction and cortical thickening).
Results PLB presented with extension into the soft tissue in
22 (76%) of 29 patients, was only subtle in three of these
22 patients, and was absent in seven patients. Signal intensity
(SI) of the soft-tissue part was most frequently homoge-
neously isointense with muscle on T1-weighted images
(90%) and high on T2-weighted images (91%). Enhance-
ment was predominantly homogeneous and diffuse (82%).
In 93% of patients cortical bone appeared abnormal: among
those patients complete cortical disruption was seen in
28%, with extension into soft tissues in all but one patient;
a permeative pattern of destruction was present in 52% of
patients, 66% of these had an associated soft-tissue mass.
Two patients with normal-appearing cortical bone had no
extension into soft tissues. In two patients focal cortical
destruction was noticed; in one patient cortical bone was
homogeneously thickened, and in one patient PLB was
selectively localized within the cortical bone. SI of the bone
marrow tumor component was more frequently heteroge-
neous (in 54%), compared with the soft-tissue component,
being high on T2-weighted images in 89%, intermediate in
7% and low in 4%. Similarly, enhancement was heteroge-
neous in 59%.
Conclusion The MR imaging appearance of PLB is
variable. In 31% of PLB patients, the tumor was intra-
osseous, with linear cortical signal abnormalities or even
normal-appearing or thickened cortical bone without soft-
tissue mass, and, as such, PLB may not infrequently look
non-aggressive on MR imaging.
Keywords Lymphoma . Tumor . Bone .MR imaging
Introduction
Primary lymphoma of bone (PLB) is a rare disease,
accounting for less than 1% of all non-Hodgkin’s lymphoma
(NHL) cases and 3–5% of all extra-nodal lymphoma cases
[1–3]. According to the World Health Organization (WHO)
classification of hematological malignancies, it is a distinct
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clinico-pathological subtype of extra-nodal, diffuse, large
B-cell lymphoma (DLBCL) with a relatively homogeneous
pathological and clinical presentation [4, 5]. Almost all
tumors are of the large B-cell type, morphologically com-
posed of large centroblastic cells, frequently with multi-
lobated nuclei [5–8]. The prognosis of PLB, depending on
staging and histologic classification, is favorable following
combined modality (chemo- and radiation) therapy, with a
5-year overall survival rate that extends to 88% [7, 9–12].
Debates are ongoing as to whether there is a uniform
imaging pattern in PLB, in particular on the magnetic
resonance (MR) imaging characteristics of PLB. Some
authors have stated that a tumor with normal-appearing
cortical bone and a substantial soft-tissue mass is likely to
be a non-Hodgkin’s lymphoma [13, 14]. One study focused
on the hypointense signal intensities on T2-weighted
images as a feature that may be characteristic of PLB as
opposed to other malignant tumors [15]. In other studies
MR findings were found to be non-specific and not useful
for differentiating PLB from other small, blue, round cell
tumors, including Ewing’s sarcoma and small cell osteosar-
coma and (in older age groups) tumors such as metastases
of carcinoma and plasmacytoma [16]. In addition, the plain
radiographic appearance of PLB differs from virtually
normal to a severely permeative pattern of bone destruction
with a blastic, lytic or mixed appearance, and, as such, is
also non-specific [17–19].
The order of differential diagnosis is, therefore, mainly
based on the patient’s age, race and clinical features.
To assess the homogeneity or heterogeneity of MR
imaging characteristics in PLB, and to assess the rate of
a non-aggressive MR imaging appearance, we evaluated
various features known from the literature, with emphasis
on cortical bone manifestation and marrow and soft-tissue
signal characteristics, in 29 patients in the present retro-
spective imaging study.
Subjects and methods
The files of 29 patients with a histologically proven diagnosis
of PLB, and MR imaging studies available at the time of
diagnosis, were retrieved from the archive of the Netherlands
Committee on Bone Tumors, representing the period between
1989 and 2004. All histological diagnosis were re-assured for
this study.
Patients’ characteristics
The study group consisted of 29 patients, 14 female and 15
male. In the majority of the patients the tumors were
located in the femur (n=13) or humerus (n=6).
Other tumor sites included the ilium (n=4), scapula
(n=2), tibia, acetabulum, lumbar vertebra and mandibula
(one patient each). The age of the patients ranged from
19–81 years (median 40 years).
MRI
Since the Netherlands Committee on Bone Tumors serves
as a consulting medium for the entire country, MRI studies
were performed on different imagers with field strengths
between 0.5 T and 1.5 T. T1-weighted spin echo (SE)
sequences were available for 28 patients; TRs varied from
400–800 ms, with TEs from 12–25 ms. T2-weighted (fast)
SE sequences were available for 29 patients, with fat-
selective pre-saturation sequences for 14 patients. TRs
varied from 2,000–7,000 ms, with TEs from 70–130 ms.
Contrast-enhanced, T1-weighted, SE series after intra-
venous injection of 0.2 mmol gadopentetate dimeglumine
(Gd-DTPA) were available for 25 of 29 patients, with fat-
selective pre-saturation sequences for ten patients. A
dynamic contrast-enhanced sequence was used for only
three patients. For all patients a combination of axial and
longitudinal (either coronal or sagittal) images was avail-
able for evaluation.
Imaging evaluation
The following parameters were evaluated in consensus by
two experienced musculoskeletal radiologists:
Tumor size Tumor dimensions were established by mea-
suring length, width and depth, assessed from the combi-
nation of axial and longitudinal images.
Extension into the soft tissues Presence or absence of a soft-
tissue component, defined as a mass beyond the margins of
cortical bone and periosteum, was determined.
Soft-tissue edema Soft-tissue edema was considered to be
present when areas of peri-lesional high signal intensity (SI)
were noticed on T2-weighted sequences and/or contrast-
enhanced T1-weighted sequences in an ill-defined feathery
pattern, without disruption of the fascial planes.
Signal intensities of soft-tissue part SIs were defined as
predominantly high, intermediate, low or mixed, relative to
muscle SI, assessed on both T1- and T2-weighted sequences.
Furthermore, homogeneity or heterogeneity of the SI on
T2-weighted images was assessed.
Enhancement of soft-tissue part The pattern of tumoral
enhancement on T1-weighted Gd-DTPA-enhanced sequences
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(absent, peripheral or diffuse) was recorded, as well as the
homogeneity or heterogeneity.
Cortical bone destruction Appearance of the cortical bone
was determined as normal or abnormal on both T1- and T2-
weighted images. Abnormal cortical bone appearance was
subdivided into complete cortical destruction (normal low
SI, completely replaced by high signal intensity of tumor),
focal destruction (normal low signal intensity, partially
replaced by high SI of tumor with focal disturbance of
cortical integrity), permeative destruction (fine linear
pattern of intracortical high SI, without disturbance of
cortical integrity) or cortical thickening (thickening of
cortical bone, without signal abnormalities).
Bone marrow involvement SIs of the bone marrow com-
ponent and homogeneity were assessed on T1- and T2-
weighted sequences, compared with muscle SI (higher,
equal/intermediate, lower, mixed) and opposed to the high
SI of normal bone marrow. Tumor margins were defined as
sharp or unsharp.
Enhancement of bone marrow component The presence or
absence of intra-osseous tumoral enhancement and the
pattern (homogeneous, heterogeneous, focal, diffuse) of
enhancement on static T1-weighted Gd-DTPA-enhanced
sequences were determined.
Histological classification and immunohistochemistry The
pathology diagnosis was established according to the World
Health Organization classification on biopsy material, using
standard histological criteria and immunohistochemistry
using antibodies directed against vimentin, CD45, CD3,
CD20, CD79a, and CD99. Immunohistochemical staining
was performed on 4 μm sections of formalin-fixed,
paraffin-embedded tissues, using standard procedures. In
this study, all tumors were of the large B-cell type.
Results
Tumor size The mean maximum tumor diameter was 11 cm
(range 3–18 cm).
Extension into the soft tissues Tumor extension into the soft
tissues was apparent in 22 of the 29 patients (Fig. 1) (76%),
in three of these patients this was very discrete (Fig. 2). In
the remaining seven patients (24%), the tumor was entirely
confined to the intramedullary and/or cortical compartment
(Fig. 3).
Soft-tissue edema Peri-lesional soft-tissue edema was en-
countered in approximately half of the patients (15 out of
29, 52%), whereas, in the other 14 patients, it was absent.
Signal intensities of soft-tissue part Appearance on T1-
weighted sequences could be assessed for 21 patients
bearing tumors with extension into the soft-tissues: in 19
(90%) of these 21 patients the SI was intermediate and
equal to that of muscle. In two patients the SI was higher
than for muscle. In 22 patients the SI on T2-weighted
sequences could be assessed, being high (higher than that
of muscle, lower than that of fat) in 20 patients (91%). This
high signal was predominantly homogeneous in 18 of those
20 patients and heterogeneous in the other four.
Fig. 1 An 80-year-old male
patient with primary non-
Hodgkin’s lymphoma of the
proximal humerus. Axial T1-
weighted turbo-spin echo (TSE)
(TR/TE 575/15 ms) images be-
fore (a) and after (b) Gd-DTPA
administration, the latter se-
quence with fat-selective pre-
saturation. Intra-osseous tumor
with circumferential substantial
extension into the soft tissue.
There is partly complete cortical
disruption of cortical bone and
otherwise permeative destruc-
tion shown as a fine linear
pattern of abnormal increased
cortical SI (a), even more con-
spicuous on contrast-enhanced
images (b, arrow)
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Enhancement of soft-tissue part Enhancement of the soft-
tissue component of the tumor could be determined in 17
patients; for the other 12 patients contrast-enhanced studies
were not available. Enhancement of the soft-tissue part
occurred in all evaluable patients, being predominantly
homogeneous and diffuse in 14 (82%) patients and
heterogeneous in the other three patients (Fig. 1).
Cortical bone destruction For two of the 29 patients the
entire cortical bone was scored as normal. In those two
patients there was also no extension into soft-tissue (Fig. 3).
In 27 patients (93%) the cortical bone was abnormal. A
permeative cortical destruction pattern was noticed for a
small majority of patients (15 of 29, 52%). In ten of these
15 patients, an associated soft-tissue mass was apparent
(Fig. 4); however, in two patients, this was absent. In the
remaining three patients only limited extra-cortical abnor-
malities were present (Fig. 2). Complete cortical disruption
was found in eight patients (Fig. 1) (28%). All but one of
these eight patients had significant extension into the soft-
tissue. Focal destruction was seen in two patients, and
homogeneous cortical thickening in one patient. Moreover,
selective intracortical tumor localization was encountered in
one other patient.
Bone marrow involvement Signal intensity of the intra-
osseous tumor component on T1-weighted images could be
assessed in 26 patients being predominantly intermediate
(equal to muscle) in 25 patients (Figs. 1, 4) and predom-
inantly low (lower than muscle) in one patient. In three
patients (12%) of the former group, a combination of
intermediate and low signal intensity was found. Demarcation
in the longitudinal extent was scored as sharp in 11 and
shaded in nine patients. On T2-weighted images (available
in 28 patients) the SI of the bone marrow compartment was
high in 25 patients (89%), intermediate in two patients (7%)
Fig. 3 A 26-year-old female
patient with primary non-
Hodgkin’s lymphoma of the
distal femur. Sagittal (a)
and axial (b) T1-weighted
contrast-enhanced fat-
suppressed turbo-spin echo
(TSE) (TR/TE 600/20 ms)
images. There is inhomoge-
neous enhancement of the intra-
osseous tumor, with normal
appearing cortical bone and,
besides enhancing periosteum,
no associated soft tissue mass
Fig. 2 A 32-year-old female
patient with primary non-
Hodgkin’s lymphoma of the
distal femur diaphysis. Axial
T2-weighted fat-suppressed
turbo-spin echo (TSE) (TR/TE
3799/80 ms) image (a) and axial
T1-weighted contrast-enhanced
fat-suppressed TSE (TR/TE
500/15 ms) image (b). Hetero-
geneous high SI (a) of intra-




with linear intracortical in-
creased SI, particularly seen on
Gd-enhanced images (b, arrow)
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and low in one patient. The SI of the bone marrow tumor
component was homogeneous in 13 of 28 patients (46%),
however, inhomogeneous in 15 patients (54%). (Figs. 2, 5).
Enhancement of bone marrow component Enhancement of
the bone marrow tumor component could be assessed in 23
patients. No enhancement was noticed in only one patient.
The other 22 patients showed enhancement, which was
homogeneous in nine patients (41%), and heterogeneous in
13 patients (59%) (Figs. 2, 3, 5).
Discussion
Primary non-Hodgkin’s lymphoma of bone (PLB) is a rare
entity among musculoskeletal tumors, and it is also un-
common among extra-nodal sites of NHL. The morphology
of these lymphomas is identical to that of lymphomas at
other sites, but the clinical course is often more protracted.
Prognosis of PLB depends mainly on staging and on his-
tological classification, but, generally, the clinical outcome,
after treatment with combined chemo- and radiation
therapy, is favorable, with a 5-year overall survival rate
rising to 88% [1–5, 9–11, 18, 20]. On the other hand, Lewis
et al. reported a 5-year survival rate of 58% and no
statistically significant difference between PLB and sys-
temic bone lymphoma [6]. With regard to histological
subtype, tumor localization and clinical presentation,
patients with PLB display homogeneous clinicopathologi-
cal features [4, 5]. Almost all tumors are localized in long
bones (particularly the femur, tibia, pelvis and humerus),
and patients present with pain and/or a palpable mass. The
literature describes a significant male preponderance, which
is not confirmed in this present study. Although PLB presents
in a wide age range of patients, evenly distributed among
the second through eighth decades of life, in general, it is
more frequently encountered in patients over 30 years of
age, with a peak incidence in the fifth decade, in contrast to
that of Ewing’s sarcoma and osteosarcoma [6, 8, 10, 11, 13,
14, 18]. In the latter patient group, a significant decrease in
incidence is found beyond the third decade. In our study
group of 29 patients a broad range of ages at presentation
was also found (19–81 years); the median age was 40 years.
Plain radiographs of PLB often show destructive bone
lesions, generally with periosteal layering and cortical
disruption. On the other hand, plain radiographs of PLB
may appear virtually normal or non-specific and can be
overlooked as being normal. As such, there is no specific
conventional radiographic pattern, and the radiographic
differential diagnosis of PLB includes a broad spectrum of
both benign (including osteomyelitis) and malignant (such
as osteosarcoma, Ewing’s sarcoma) lesions [8, 16–19].
These tumors and tumor-like lesions may demonstrate
similar radiographic features but warrant different types of
therapy. In this respect PLB is associated with a better
prognostic outcome than that for other small round cell
tumors. Literature on the presentation of MR imaging
features of PLB is relatively scarce and contradictory. These
studies, frequently with limited numbers of patients, mainly
focused on the appearance of the cortical bone, relative to
associated soft-tissue abnormalities, and on SI character-
istics [13–16, 18, 19, 21, 22]. Low SI on T2-weighted
sequences has been mentioned as a feature of PLB,
probably due to a high content of fibrous tissue [15]. We
could not confirm this feature to a great extent in our
Fig. 4 A 58-year-old male patient with primary non-Hodgkin’s
lymphoma of the distal humerus. Axial T1 turbo-spin echo (TSE)
(TR/TE 504/13 ms) (a) and T2-weighted TSE (5,927/80 ms) image
with fat-selective pre-saturation (b). Primary intra-osseous tumor with
circumferential soft-tissue mass, homogeneously isointense on T1 and
high on T2-weighted sequences. Normal cortical thickness with
discrete signal abnormalities on T1 (a, arrow), more conspicuous on
T2-weighted sequences (b)
Skeletal Radiol (2007) 36:937–944 941
population. Low SI on T1- or T2-weighted sequences was
present in only one patient each. Almost all tumors showed
a non-specific combination of intermediate (equal to that of
muscle) SI on T1-weighted sequences and high SI on T2-
weighted sequences.
Several studies on PLB and MR imaging focused on the
pattern of cortical destruction in order to use it as a
differentiating criterion. It was stated that a tumor with a
normal (appearing) cortex and a substantial soft-tissue mass
is likely to be lymphoma [13, 14]. MR imaging may show
small linear foci of intermediate or high SI on T2-weighted
sequences, penetrating the cortical bone. This MR pattern
of permeative cortical destruction is, however, not specific
to lymphoma. It can be seen in other small round cell
tumors (in the younger age group) as well as in different
metabolic and inflammatory processes, including hyper-
parathyroidism and osteomyelitis and, for instance, myeloma
or metastatic carcinoma (in the older age group) [13, 14]. In
our study, cortical abnormalities were present in 93% of
patients, and extension into the soft tissue was found in
76%, but various types of destruction and combinations
with or without such extension were recognized (Table 1).
A pattern of permeative cortical destruction with linear foci
of abnormal SI was noticed in 15 of the 29 (52%) patients.
Ten of these 15 patients had a definite soft-tissue mass. In
five patients, however, this was minimal or even absent. In
28% of our patient population complete cortical disruption
could be appreciated; in all but one patient it was
accompanied by a large soft-tissue mass. In another two
patients, the cortical bone appeared to be completely
normal, and in these patients there was no associated soft-
tissue mass. In one patient with histologically confirmed
PLB the tumor was selectively located within the cortical
bone, without further extension into the soft tissue and/or
bone marrow involvement. In one patient the cortical bone
was homogeneously thickened, a feature that can also be
encountered in reactive processes (after trauma or infec-
tion). Peri-osteal or cortical lymphoma without medullary
involvement is a very rare manifestation of NHL, but it
has been previously described [23]. In this respect, it can
be concluded that in patients with PLB the pattern of
cortical destruction is heterogeneous and non-specific.
MR imaging is the optimal modality to demonstrate the
extent of bone marrow replacement by PLB, particularly
using T1-weighted sequences [14, 24]. Multi-centric bone
marrow disease is likely to be detected by longitudinal
series with a large field of view. Signal intensities of the
bone marrow component were non-specific in the present
series, being intermediate on T1-weighted sequences and
high on T2-weighted sequences in almost all patients. In
Fig. 5 A 29-year-old male pa-
tient with non-Hodgkin’s lym-
phoma of the proximal humerus.
Axial T1-weighted contrast-en-
hanced (TR/TE 550/12 ms) (a)
and T2-weighted (b) turbo-spin
echo (TSE) (TR/TE 3,021/
80 ms) images with fat-selective
pre-saturation. Intra-osseous tu-
mor localization with no exten-
sion into soft-tissue and
heterogeneous high SI on both
sequences
Table 1 Relationship between
MR imaging appearance of
cortical bone and extension
into the soft tissue in 29
patients with PLB







Normal 0 0 2 2
Permeative destruction 10 3 2 15
Focal disruption 2 0 0 2
Complete disruption 7 0 1 8
Cortex thickening 0 0 1 1
Tumor within cortex only 0 0 1 1
Total 19 3 7 29
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only three patients a combination of intermediate and low
signal intensity was found. Demarcation in the longitudinal
extent was scored as sharp in 11 and unsharp in nine
patients. The SI of the bone marrow tumor component was
homogeneous in 13 of 28 patients (46%); however, it was
inhomogeneous in 15 patients (54%), which can be
explained by the intermingling of normal bone marrow
between areas of tumor. Contrast-enhanced images of the
bone marrow showed a similar distribution; enhancement
was diffuse and homogeneous in 41% and heterogeneous in
59% of the patients whose condition was eligible for
evaluation. Opposed to the bone marrow component, the
soft- tissue component, if present, was far more homoge-
neous, both on T1-weighted contrast-enhanced images
(82%) and as high SI on T2-weighted images (82%).
The data obtained in this retrospective study demonstrate
that, in contrast to the relatively homogeneous clinical and
pathological presentation, the MR imaging features are not
uniform in patients with PLB. Although the majority of our
patients displayed a combination of definite cortical abnor-
malities (either permeative destruction or complete disrup-
tion) and extension into soft-tissue, lymphoma may show
different appearances. Particularly, intra-osseous lesions
with linear cortical signal abnormalities without substantial
soft-tissue mass, or even normal-appearing or thickened
cortical bone without soft-tissue mass, may look non-
aggressive and even benign. In the present study no fewer
than nine of 29 patients (31%) with PLB presented in that
manner. Radiologists should thus be aware of that in the
right clinical context.
There are several limitations concerning this retrospec-
tive and largely descriptive study. The data obtained were
collected from various institutions that had used different
MR imaging systems, field strengths and protocols. In order
to collect a larger number of patients, given the rarity of
PLB, we could not avoid this. The assessment of hetero-
geneity or homogeneity of signal characteristics is quite
subjective; however, for the goal of this study it was of
minor importance. Fast dynamic contrast-enhanced sequen-
ces were used only incidentally. Nowadays, these acquisi-
tions are widely used to assess the biologic behavior of
primary bone and soft-tissue tumors and to determine the
response to chemo- and/or radiation therapy. With regard to
PLB, the rapid decrease of tumor volume and the complete
disappearance of the soft-tissue component on MR imaging
has been described as a significant indicator of good
response to treatment [24]. In this respect, MR imaging
has a direct impact on individual patient care, which is
however, outside the scope of this study. We could not
determine how MR imaging had caused any change in
clinical approach in the patients with PLB described here.
Differentiating PLB from other malignant small round cell
tumors, on the one hand, or reactive processes, on the other
hand, based on (MR) imaging criteria only, is, in our
opinion, not possible and not useful, which stresses the
need for accurate core biopsy, which is definitely crucial for
both diagnosis and staging purposes.
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